Recursion CEO sells 22,408 shares at $3.52

CEO Najat Khan executed a pre-planned sale of 22,408 RXRX shares and now directly holds 2,072,890 shares.

Rhea-AI Filing Summary

RECURSION PHARMACEUTICALS, INC. (RXRX) reported that CEO and President Najat Khan sold 22,408 shares of Class A Common Stock on September 8, 2026, in an open-market transaction under a Rule 10b5-1 trading plan. The weighted average sale price was $3.5176 per share, based on trades between $3.485 and $3.58. After this sale, Khan directly held 2,072,890 shares of Class A Common Stock.

Insider Trade Summary 10b5-1

Net Seller: 22,408 shares

Net Sell 1 txn

Insider Khan Najat

Role CEO and President

Sold 22,408 shs ($79K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1, F2	22,408	$3.5176	$79K

Holdings After Transaction: Class A Common Stock — 2,072,890 shares (Direct)

Footnotes (2)

1. F1. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2025.
2. F2. This transaction was executed in multiple trades at prices ranging from $3.485 to $3.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Key Figures

Shares sold: 22,408 shares Weighted average sale price: $3.5176 per share Trade price range: $3.485–$3.58 per share +2 more

5 metrics

Shares sold 22,408 shares Class A Common Stock sold by the CEO on September 8, 2026

Weighted average sale price $3.5176 per share Open-market sale on September 8, 2026

Trade price range $3.485–$3.58 per share Price range across multiple trades on September 8, 2026

Shares held after transaction 2,072,890 shares CEO’s direct Class A Common Stock holdings after the sale

Rule 10b5-1 plan adoption date September 22, 2025 Date the CEO adopted the trading plan used for this sale

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, Class A Common Stock

3 terms

Rule 10b5-1 trading plan regulatory

"This transaction is pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

Class A Common Stock financial

"This transaction was executed in multiple trades at prices"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

FAQ

What insider transaction did RXRX CEO Najat Khan report?

Najat Khan, CEO and President of RXRX, reported selling 22,408 shares of Class A Common Stock on September 8, 2026, in an open-market transaction pursuant to a Rule 10b5-1 trading plan.

At what price were the RXRX shares sold by the CEO?

The CEO’s sale used a weighted average price of $3.5176 per share, with individual trades executed at prices ranging from $3.485 to $3.58.

How many RXRX shares does CEO Najat Khan hold after this sale?

After the reported sale, Najat Khan directly holds 2,072,890 shares of RXRX Class A Common Stock.

Was the RXRX insider sale made under a Rule 10b5-1 trading plan?

Yes. The transaction was made pursuant to a Rule 10b5-1 trading plan that Najat Khan adopted on September 22, 2025.

What type of RXRX security was involved in the CEO’s transaction?

The transaction involved Class A Common Stock of RECURSION PHARMACEUTICALS, INC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 05:56 PM Accepted by SEC EDGAR 09/10/2026 - 05:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Khan Najat

(Last) (First) (Middle)

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UTAH 84101

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/08/2026		S(1)		22,408	D	$3.5176(2)	2,072,890	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2025.

2. This transaction was executed in multiple trades at prices ranging from $3.485 to $3.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Remarks:

	/s/ Kyle Nelson, attorney-in-fact	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)